Discontinued — last reported Q4 '24
HCA Healthcare Business Sale Proceeds increased by 820.0% to $92.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 475.0%, from $16.00M to $92.00M. Over 4 years (FY 2021 to FY 2025), Business Sale Proceeds shows a downward trend with a -40.6% CAGR.
An increase signals portfolio optimization or a strategic pivot, while a lack of proceeds suggests a stable, long-term asset base.
This metric represents the cash inflows received from the divestiture or sale of business segments, product lines, or su...
Occurs sporadically; peers often divest legacy segments to focus on high-margin innovation areas like continuous glucose monitoring or diagnostics.
cf_proceeds_from_sale_of_business| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.00M | $1.95B | $180.00M | $14.00M | $6.00M | $632.00M | $585.00M | $165.00M | $7.00M | $11.00M | $10.00M | $310.00M | $1.00M | $1.00M | $16.00M | $161.00M | $6.00M | $10.00M | $92.00M |
| QoQ Change | — | >999% | -90.8% | -92.2% | -57.1% | >999% | -7.4% | -71.8% | -95.8% | +57.1% | -9.1% | >999% | -99.7% | +0.0% | >999% | +906.3% | -96.3% | +66.7% | +820.0% |
| YoY Change | — | — | — | — | -40.0% | -67.6% | +225.0% | >999% | +16.7% | -98.3% | -98.3% | +87.9% | -85.7% | -90.9% | +60.0% | -48.1% | +500.0% | +900.0% | +475.0% |